Abstract
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. HCC patients have a poor prognosis due to shortage of effective therapies though a small proportion of patients are eligible for curative treatments. Precision medicine, a recently emerging medicinal model, has provided more avenues in the management of HCC.
Methods: Published literatures related to HCC and precision medicine were reviewed. The article aims to discuss the recent progress of HCC therapy under the guidance of precision medicine, and the major obstacles for its application.
Results: Sorafenib remains the only first-line drug proved for treating advanced HCC, though it displays limited beneficial effects. Advances have been achieved in the technologies of new generation sequencing and molecular biology, bioinformatics, big data and cloud computing frame. Recent progresses in seeking tumor biomarkers and oncogenic addiction loops, re-analyses of failed clinical trials, techniques of circulating tumor cells and liquid biopsy, new clinical designs based on molecular information have offered a glimmer of hope in combating HCC. However, there are many obstacles, such as high heterogeneity, unpredictable driver genes, oncogenetic addiction loops and actionable events and drug resistance.
Conclusion: The future progress in interdisciplinary application of computing, mathematics and information in medicine may further promote the development of precision medicine in the prevention, diagnosis, treatment and monitoring of HCC. We hope this article can provide some new clues for clinicians and scientists engaged in the clinical and basic research of HCC.
Keywords: Hepatocellular carcinoma, precision medicine, personalized medicine, sorafenib, bioinformatics, tumor biomarkers.
Graphical Abstract
Clinical Cancer Drugs
Title:Progress and Obstacles in the Application of Precision Medicine in the Management of Hepatocellular Carcinoma
Volume: 4
Author(s): Ping Wang and Xueying Sun*
Affiliation:
- The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001,China
Keywords: Hepatocellular carcinoma, precision medicine, personalized medicine, sorafenib, bioinformatics, tumor biomarkers.
Abstract: Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. HCC patients have a poor prognosis due to shortage of effective therapies though a small proportion of patients are eligible for curative treatments. Precision medicine, a recently emerging medicinal model, has provided more avenues in the management of HCC.
Methods: Published literatures related to HCC and precision medicine were reviewed. The article aims to discuss the recent progress of HCC therapy under the guidance of precision medicine, and the major obstacles for its application.
Results: Sorafenib remains the only first-line drug proved for treating advanced HCC, though it displays limited beneficial effects. Advances have been achieved in the technologies of new generation sequencing and molecular biology, bioinformatics, big data and cloud computing frame. Recent progresses in seeking tumor biomarkers and oncogenic addiction loops, re-analyses of failed clinical trials, techniques of circulating tumor cells and liquid biopsy, new clinical designs based on molecular information have offered a glimmer of hope in combating HCC. However, there are many obstacles, such as high heterogeneity, unpredictable driver genes, oncogenetic addiction loops and actionable events and drug resistance.
Conclusion: The future progress in interdisciplinary application of computing, mathematics and information in medicine may further promote the development of precision medicine in the prevention, diagnosis, treatment and monitoring of HCC. We hope this article can provide some new clues for clinicians and scientists engaged in the clinical and basic research of HCC.
Export Options
About this article
Cite this article as:
Wang Ping and Sun Xueying *, Progress and Obstacles in the Application of Precision Medicine in the Management of Hepatocellular Carcinoma, Clinical Cancer Drugs 2017; 4 (2) . https://dx.doi.org/10.2174/2212697X04666170817125451
DOI https://dx.doi.org/10.2174/2212697X04666170817125451 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry Bioactive Metabolites from Pathogenic and Endophytic Fungi of Forest Trees
Current Medicinal Chemistry C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Effects of Crosstalks Between Sumoylation and Phosphorylation in Normal Cellular Physiology and Human Diseases
Current Molecular Medicine Targeting Hepatitis B Virus and Human Papillomavirus Induced Carcinogenesis: Novel Patented Therapeutics
Recent Patents on Anti-Infective Drug Discovery Epivention: Epigenetic Based Cancer Chemoprevention
Epigenetic Diagnosis & Therapy (Discontinued) Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Preface
Clinical Cancer Drugs Identification of Vβ7.1_H3F7 as a Therapeutic Gene Encoding TCR Specific to Hepatocellular Carcinoma
Current Gene Therapy <i>In silico</i> and <i>In vitro</i> Investigation of a Likely Pathway for Anti-Cancerous Effect of Thrombocidin-1 as a Novel Anticancer Peptide
Protein & Peptide Letters Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg
Protein & Peptide Letters Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Can We Effectively Degrade Microcystins? - Implications on Human Health
Anti-Cancer Agents in Medicinal Chemistry Characterization of Stem-Like Cells Directly Isolated from Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens
Current Stem Cell Research & Therapy Osteopontin: An Effector and an Effect of Tumor Metastasis
Current Molecular Medicine